Skip to main content
. 2015 Dec;12(4):362–374. doi: 10.7497/j.issn.2095-3941.2015.0063

Table 2. Most commonly used Pt-based combination regimens suggested by NCCN.

Drug/regimen Indications Dosage and schedule (could be variable)
Cisplatin, fluorouracil (PF) Anal, bladder, cervical, esophageal, gastric, and head and neck cancer Cisplatin 75-100 mg/m2 IV on days 1 and 29;
Fluorouracil 750-1,000 mg/m2 IV continuous infusion over 24 h daily on days 1-4 and 29-32;
35-day cycle
Cisplatin, etoposide (EP/PE) NSCLC, SCLC, ovarian, prostate, testicular, thymic, and neuroendocrine cancer Cisplatin 80 mg/m2 day 1 and etoposide 100 mg/m2 days 1, 2, 3
Carboplatin, etoposide (EC) SCLC, ovarian, prostate, testicular, and neuroendocrine cancer; soft tissue sarcoma Carboplatin AUC 5-6 day 1 and etoposide 100 mg/m2 days 1, 2, 3
Carboplatin, paclitaxel (TC/TP) Breast, cervical, ovarian, endometrial, esophageal, gastric, thymic, and thyroid cancer; melanoma; NSCLC Paclitaxel 175 mg/m2 IV over 3 h followed by carboplatin AUC 56 IV over 1 h day 1 repeat every 3 weeks × 6 cycles
Oxaliplatin, leucovorin, fluorouracil (FLOFOX) Colorectal cancer Oxaliplatin 85 mg/m2 IV over 2 h, day 1;
leucovorin 400 mg/m2 IV over 2 h, day 1;
5-FU 400 mg/m2 IV bolus on day 1, and then 1,200 mg/m2/day × 2 days (total 2,400 mg/m2 over 46-48 h) IV continuous infusion; repeat every 2 weeks
Oxaliplatin, capecitabine (CAPOX/XELOX) Colorectal, esophagus, and gastric cancer Oxaliplatin 130 mg/m2 IV over 2 h, day 1;
capecitabine 850-1,000 mg/m2 twice daily PO for 14 days;
repeat every 3 weeks